We participated in consultations held by the pan-Canadian Pharmaceutical Alliance (pCPA), an federal organization that determines whether or not it will enter into a negotiation for a drug and negotiates terms of an agreement with a drug manufacturer.  We developed a submission about the pCPA Temporary Access Process (pTAP) and emphasized the meaningful and active inclusion of patients and patient organizations in their work. Learn more by reading our submission.